Abstract:BackgroundHeterozygous loss-of-function mutations in the progranulin gene (GRN) lead to frontotemporal lobar degeneration (FTLD) while the complete loss of progranulin (PGRN) function results in neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disease. Thus the growth factor-like protein PGRN may play an important role in lysosomal degradation. In line with a potential lysosomal function, PGRN is partially localized and processed in lysosomes. In the central nervous system (CNS), PGRN is like other lysosomal proteins highly expressed in microglia, further supporting an important role in protein degradation. We have previously reported that cathepsin (Cat) D is elevated in GRN-associated FTLD patients and Grn knockout mice. However, the primary mechanism that causes impaired protein degradation and elevated CatD levels upon PGRN deficiency in NCL and FTLD remains unclear.MethodsmRNA expression analysis of selected lysosomal hydrolases, lysosomal membrane proteins and autophagy-related genes was performed by NanoString nCounter panel. Protein expression, maturation and in vitro activity of Cat D, B and L in mouse embryonic fibroblasts (MEF) and brains of Grn knockout mice were investigated. To selectively characterize microglial and non-microglial brain cells, an acutely isolated microglia fraction using MACS microbeads (Miltenyi Biotec) conjugated with CD11b antibody and a microglia-depleted fraction were analyzed for protein expression and maturation of selected cathepsins.ResultsWe demonstrate that loss of PGRN results in enhanced expression, maturation and in vitro activity of Cat D, B and L in mouse embryonic fibroblasts and brain extracts of aged Grn knockout mice. Consistent with an overall enhanced expression and activity of lysosomal proteases in brain of Grn knockout mice, we observed an age-dependent transcriptional upregulation of certain lysosomal proteases. Thus, lysosomal dysfunction is not reflected by transcriptional downregulation of lysosomal proteases but rather by the upregulation of certain lysosomal proteases in an age-dependent manner. Surprisingly, cell specific analyses identified early lysosomal deficits in microglia before enhanced cathepsin levels could be detected in other brain cells, suggesting different functional consequences on lysosomal homeostasis in microglia and other brain cells upon lack of PGRN.ConclusionsThe present study uncovers early and selective lysosomal dysfunctions in Grn knockout microglia/macrophages. Dysregulated lysosomal homeostasis in microglia might trigger compensatory lysosomal changes in other brain cells.

ASO-mediated knockdown of GPNMB in mutant-GRN and Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses

Progranulin loss results in sex-dependent dysregulation of the peripheral and central immune system

Investigating the Role and Regulation of GPNMB in Progranulin-deficient Macrophages

Early lysosomal maturation deficits in microglia triggers enhanced lysosomal activity in other brain cells of progranulin knockout mice

Exaggerated Inflammation, Impaired Host Defense, and Neuropathology in Progranulin-Deficient Mice

Identification of biological pathways regulated by PGRN and GRN peptide treatments using transcriptome analysis

Neuronal Effects of Progranulin Deficiency Contribute to Frontotemporal Dementia Independent of Neuroinflammation

Peripheral expression of brain-penetrant progranulin rescues pathologies in mouse models of frontotemporal lobar degeneration

Progranulin Protects Against Amyloid Β Deposition and Toxicity in Alzheimer’s Disease Mouse Models

Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases

Antisense oligonucleotides targeting the miR-29b binding site in the GRN mRNA increase progranulin translation

Progranulin Does Not Bind Tumor Necrosis Factor (TNF) Receptors and is Not a Direct Regulator of TNF-Dependent Signaling or Bioactivity in Immune or Neuronal Cells

Elevated Progranulin Contributes to Synaptic and Learning Deficit Due to Loss of Fragile X Mental Retardation Protein.

Progranulin as a therapeutic target in neurodegenerative diseases

PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, GBA1 mutation-associated pathologies and diseases.

Targeting Progranulin as an Immuno-Neurology Therapeutic Approach

Progranulin from different gliocytes in the nucleus accumbens exerts distinct roles in FTD- and neuroinflammation-induced depression-like behaviors

Pathogenic cysteine mutations affect progranulin function and production of mature granulins.

The role of progranulin in macrophages of a glioblastoma model

Lysosomes cell autonomously regulate myeloid cell states and immune responses

Analysis of the Biomarkers for Neurodegenerative Diseases in Aged Progranulin Deficient Mice